Harnessing the cell cycle to treat cancer and other serious diseases
As a clinical-stage, biopharmaceutical company, we develop innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates to address oncology and hematology indications.
Cyclacel is a pioneer in the field of cell cycle biology to treat cancer. We use insights in cancer biology to research and develop medicines that address the growing problem of resistance. Cancer cells learn to evade anticancer therapeutics and become resistant to available therapies. We aim to suppress mechanisms of resistance and reactivate the body’s own cell death mechanisms to destroy cancer cells.
Consistent with our mission to develop medicines that expand available options for patients, we have 2 orally-available programs in clinical development:
- Fadraciclib (formerly CYC065), a cyclin dependent kinase (CDK)-2 and-9 inhibitor
- Plogosertib (formerly CYC140), a polo-like kinase 1 (PLK1) inhibitor
Check out the latest news.
Access the latest publications on fadraciclib, CYC140, sapacitabine and related mode of actions.
A Phase 1/2, Open-label, Multi-center Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma. A poster presentation at the 34th EORTC-NCI-AACR Symposium 26-28 Oct 2022, Abstract 50.Download PDF
A precision medicine drug discovery pipeline identifies combined CDK2 and 9 inhibition as a novel therapeutic strategy in colorectal cancer. Mol Cancer Ther. 2020, 19: 2516-2527.Download PDF